Aclaris Therapeutics, Inc. (LON:0H8T)
3.300
-0.068 (-2.02%)
At close: Feb 12, 2026
Aclaris Therapeutics Employees
As of December 31, 2024, Aclaris Therapeutics had 64 total employees, including 61 full-time and 3 part-time employees. The number of employees decreased by 27 or -29.67% compared to the previous year.
Employees
64
Change (1Y)
-27
Growth (1Y)
-29.67%
Revenue / Employee
185.89K GBP
Profits / Employee
-1.67M GBP
Market Cap
267.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 64 | -27 | -29.67% | 61 | 3 |
| Dec 31, 2023 | 91 | -14 | -13.33% | 86 | 5 |
| Dec 31, 2022 | 105 | 28 | 36.36% | 100 | 5 |
| Dec 31, 2021 | 77 | 17 | 28.33% | 72 | 5 |
| Dec 31, 2020 | 60 | -17 | -22.08% | 57 | 3 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| Integrated Diagnostics Holdings | 6,309 |
| Tristel | 267 |
| Animalcare Group | 201 |
| Avacta Group | 151 |
Aclaris Therapeutics News
- 13 days ago - Aclaris Therapeutics (ACRS) Receives Buy Rating with $10 Target - GuruFocus
- 14 days ago - Looking Into Aclaris Therapeutics Inc's Recent Short Interest - Benzinga
- 16 days ago - Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Benzinga
- 16 days ago - Aclaris Therapeutics (ACRS) Reports Promising Preclinical Outcomes for Alopecia Treatment - GuruFocus
- 16 days ago - Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) - GlobeNewsWire
- 4 weeks ago - Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages - Slideshow - Seeking Alpha
- 5 weeks ago - Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript - Seeking Alpha